Clinical profile and outcomes of hepatocellular carcinoma in primary Budd-Chiari syndrome

Table 5 Management of patients with Budd-Chiari syndrome-hepatocellular carcinoma (Mumbai center)

Age	Sex	Site of obstruction	Length of block	BCS intervention	BCS: Restenosis	BCS: Time between intervention and stent block	No. of Reinterventions for HVOTO	Time between BCS and HCC diagnosis in d	AFP	BCLC	CTP	Initial HCC management	HCC response	Survival after diagnosis of HCC until last follow-up in d	No. of lesion	Reintervention for HCC
30	M	IVC + HV	Long	Medical management	No			3500	58000	C	C	Conservative		1201	4	None
46	M	IVC+ HV	Long	Medical management	No			150	25.60	D	C	Conservative		3651	4	None
51	M	HV	Short	Medical management	No			350	1.16	D	C	Conservative		901	4	None
22	M	IVC + HV	Long	Medical management	No			460	600	C	B	Conservative		1501	3	None
35	M	IVC + HV	Long	TIPSS	No			3400	1200	D	C	Conservative		30	4	None
15	F	IVC + HV	Long	Medical management	No			240	NA	B	B	LT		10001	1	None
16	M	IVC + HV	Long	TIPSS	Yes	150	IVC angioplasty	3300	NA	B	B	LT		29001	2	None
NA	NA	IVC + HV	Long	TIPSS	No			1200	NA	B	B	Conservative		601	1	None
NA	NA	IVC +HV	Long	Medical management				400	1450	D	B	Conservative		1801	4	None

¹Alive at last follow-up. AFP: Alpha-fetoprotein; BCLC: Barcelona Clinic Liver Cancer; BCS: Budd-Chiari syndrome; CTP: Child Turcotte Pugh; F: Female; HCC: Hepatocellular carcinoma; HV: Hepatic vein; HVOTO: Hepatic venous outflow tract obstruction; IVC: Inferior vena cava; LT: Liver transplant; M: Male; NA: Not available; TIPSS: Transjugular intrahepatic portosystemic shunt.